Genotyping of mutations detected with GeneXpert

K. N'guessan Kouassi, Alagna Riccardo, C. Dutoziet Christian, Guei André, Coulibaly Férilaha, Seck Angu Hortense, Assandé Jean-marc, Cirillo Daniela Maria, Dosso Mireille

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective/background: Tuberculosis remains an important cause of mortality worldwide. Previous tuberculosis treatment is a strong determinant of multi-drug resistant tuberculosis. The study objective was to describe the mutations detected of Mycobacterium tuberculosis (MTB) complex clinical strains screened with GeneXpert isolated from previously treated patients in Côte d'Ivoire. Methods: Sputum collected and decontaminated by the n-acetyl-l-cysteine method was used to perform Ziehl-Neelsen staining, GeneXpert MTB/rifampicin, and culture on Lowenstein-Jensen medium. Drug susceptibility testing (DST) for first-line drugs was performed in a Bactec 960 Automated System. After strain identification by antigen MPT64 detection, DNA extraction, and genotyping with MTBDRplus assay was performed and interpreted. The strains muted in rpoB without a specific protein identified and were sequenced. Results: Mutant sequences were detected in 60 sputum samples with GeneXpert MTB/rifampicin of which 55 were confirmed multi-drug resistant MTB strains after DST. The most frequent mutations responsible for rifampin resistance were detected with MTBDRplus assay for 49 (81.7%) clinical strains, while sequencing was required for 11 (18.3%). H526Q mutation, L533P, and D516V associated respectively with L533P, A532A, and S522L, and were observed for three relapse cases. For these cases, GeneXpert and sequencing results were concordant. Discrepancies between GeneXpert and mycobacteria growth indicator tube-DST for rifampin were observed for three strains, on which D516Y, H526C, and L533P were identified. Conclusion: In the setting of a high prevalence of drug resistance, characterization of the genetic basis of MTB strains resistant to rifampin could be screened first with MTBDRplus.

Original languageEnglish
JournalInternational Journal of Mycobacteriology
DOIs
Publication statusAccepted/In press - Dec 23 2015

Fingerprint

Rifampin
Mycobacterium tuberculosis
Mutation
Multidrug-Resistant Tuberculosis
Sputum
Pharmaceutical Preparations
Tuberculosis
Mycobacterium
Drug Resistance
Cysteine
Staining and Labeling
Antigens
Recurrence
Mortality
DNA
Growth
Proteins
Therapeutics

Keywords

  • Molecular assays
  • Resistance
  • Rifampin
  • Tuberculosis

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

N'guessan Kouassi, K., Riccardo, A., Dutoziet Christian, C., André, G., Férilaha, C., Hortense, S. A., ... Mireille, D. (Accepted/In press). Genotyping of mutations detected with GeneXpert. International Journal of Mycobacteriology. https://doi.org/10.1016/j.ijmyco.2016.01.001

Genotyping of mutations detected with GeneXpert. / N'guessan Kouassi, K.; Riccardo, Alagna; Dutoziet Christian, C.; André, Guei; Férilaha, Coulibaly; Hortense, Seck Angu; Jean-marc, Assandé; Daniela Maria, Cirillo; Mireille, Dosso.

In: International Journal of Mycobacteriology, 23.12.2015.

Research output: Contribution to journalArticle

N'guessan Kouassi, K, Riccardo, A, Dutoziet Christian, C, André, G, Férilaha, C, Hortense, SA, Jean-marc, A, Daniela Maria, C & Mireille, D 2015, 'Genotyping of mutations detected with GeneXpert', International Journal of Mycobacteriology. https://doi.org/10.1016/j.ijmyco.2016.01.001
N'guessan Kouassi K, Riccardo A, Dutoziet Christian C, André G, Férilaha C, Hortense SA et al. Genotyping of mutations detected with GeneXpert. International Journal of Mycobacteriology. 2015 Dec 23. https://doi.org/10.1016/j.ijmyco.2016.01.001
N'guessan Kouassi, K. ; Riccardo, Alagna ; Dutoziet Christian, C. ; André, Guei ; Férilaha, Coulibaly ; Hortense, Seck Angu ; Jean-marc, Assandé ; Daniela Maria, Cirillo ; Mireille, Dosso. / Genotyping of mutations detected with GeneXpert. In: International Journal of Mycobacteriology. 2015.
@article{e65a6e9d4bec4062a4c825460e0912bc,
title = "Genotyping of mutations detected with GeneXpert",
abstract = "Objective/background: Tuberculosis remains an important cause of mortality worldwide. Previous tuberculosis treatment is a strong determinant of multi-drug resistant tuberculosis. The study objective was to describe the mutations detected of Mycobacterium tuberculosis (MTB) complex clinical strains screened with GeneXpert isolated from previously treated patients in C{\^o}te d'Ivoire. Methods: Sputum collected and decontaminated by the n-acetyl-l-cysteine method was used to perform Ziehl-Neelsen staining, GeneXpert MTB/rifampicin, and culture on Lowenstein-Jensen medium. Drug susceptibility testing (DST) for first-line drugs was performed in a Bactec 960 Automated System. After strain identification by antigen MPT64 detection, DNA extraction, and genotyping with MTBDRplus assay was performed and interpreted. The strains muted in rpoB without a specific protein identified and were sequenced. Results: Mutant sequences were detected in 60 sputum samples with GeneXpert MTB/rifampicin of which 55 were confirmed multi-drug resistant MTB strains after DST. The most frequent mutations responsible for rifampin resistance were detected with MTBDRplus assay for 49 (81.7{\%}) clinical strains, while sequencing was required for 11 (18.3{\%}). H526Q mutation, L533P, and D516V associated respectively with L533P, A532A, and S522L, and were observed for three relapse cases. For these cases, GeneXpert and sequencing results were concordant. Discrepancies between GeneXpert and mycobacteria growth indicator tube-DST for rifampin were observed for three strains, on which D516Y, H526C, and L533P were identified. Conclusion: In the setting of a high prevalence of drug resistance, characterization of the genetic basis of MTB strains resistant to rifampin could be screened first with MTBDRplus.",
keywords = "Molecular assays, Resistance, Rifampin, Tuberculosis",
author = "{N'guessan Kouassi}, K. and Alagna Riccardo and {Dutoziet Christian}, C. and Guei Andr{\'e} and Coulibaly F{\'e}rilaha and Hortense, {Seck Angu} and Assand{\'e} Jean-marc and {Daniela Maria}, Cirillo and Dosso Mireille",
year = "2015",
month = "12",
day = "23",
doi = "10.1016/j.ijmyco.2016.01.001",
language = "English",
journal = "International Journal of Mycobacteriology",
issn = "2212-5531",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Genotyping of mutations detected with GeneXpert

AU - N'guessan Kouassi, K.

AU - Riccardo, Alagna

AU - Dutoziet Christian, C.

AU - André, Guei

AU - Férilaha, Coulibaly

AU - Hortense, Seck Angu

AU - Jean-marc, Assandé

AU - Daniela Maria, Cirillo

AU - Mireille, Dosso

PY - 2015/12/23

Y1 - 2015/12/23

N2 - Objective/background: Tuberculosis remains an important cause of mortality worldwide. Previous tuberculosis treatment is a strong determinant of multi-drug resistant tuberculosis. The study objective was to describe the mutations detected of Mycobacterium tuberculosis (MTB) complex clinical strains screened with GeneXpert isolated from previously treated patients in Côte d'Ivoire. Methods: Sputum collected and decontaminated by the n-acetyl-l-cysteine method was used to perform Ziehl-Neelsen staining, GeneXpert MTB/rifampicin, and culture on Lowenstein-Jensen medium. Drug susceptibility testing (DST) for first-line drugs was performed in a Bactec 960 Automated System. After strain identification by antigen MPT64 detection, DNA extraction, and genotyping with MTBDRplus assay was performed and interpreted. The strains muted in rpoB without a specific protein identified and were sequenced. Results: Mutant sequences were detected in 60 sputum samples with GeneXpert MTB/rifampicin of which 55 were confirmed multi-drug resistant MTB strains after DST. The most frequent mutations responsible for rifampin resistance were detected with MTBDRplus assay for 49 (81.7%) clinical strains, while sequencing was required for 11 (18.3%). H526Q mutation, L533P, and D516V associated respectively with L533P, A532A, and S522L, and were observed for three relapse cases. For these cases, GeneXpert and sequencing results were concordant. Discrepancies between GeneXpert and mycobacteria growth indicator tube-DST for rifampin were observed for three strains, on which D516Y, H526C, and L533P were identified. Conclusion: In the setting of a high prevalence of drug resistance, characterization of the genetic basis of MTB strains resistant to rifampin could be screened first with MTBDRplus.

AB - Objective/background: Tuberculosis remains an important cause of mortality worldwide. Previous tuberculosis treatment is a strong determinant of multi-drug resistant tuberculosis. The study objective was to describe the mutations detected of Mycobacterium tuberculosis (MTB) complex clinical strains screened with GeneXpert isolated from previously treated patients in Côte d'Ivoire. Methods: Sputum collected and decontaminated by the n-acetyl-l-cysteine method was used to perform Ziehl-Neelsen staining, GeneXpert MTB/rifampicin, and culture on Lowenstein-Jensen medium. Drug susceptibility testing (DST) for first-line drugs was performed in a Bactec 960 Automated System. After strain identification by antigen MPT64 detection, DNA extraction, and genotyping with MTBDRplus assay was performed and interpreted. The strains muted in rpoB without a specific protein identified and were sequenced. Results: Mutant sequences were detected in 60 sputum samples with GeneXpert MTB/rifampicin of which 55 were confirmed multi-drug resistant MTB strains after DST. The most frequent mutations responsible for rifampin resistance were detected with MTBDRplus assay for 49 (81.7%) clinical strains, while sequencing was required for 11 (18.3%). H526Q mutation, L533P, and D516V associated respectively with L533P, A532A, and S522L, and were observed for three relapse cases. For these cases, GeneXpert and sequencing results were concordant. Discrepancies between GeneXpert and mycobacteria growth indicator tube-DST for rifampin were observed for three strains, on which D516Y, H526C, and L533P were identified. Conclusion: In the setting of a high prevalence of drug resistance, characterization of the genetic basis of MTB strains resistant to rifampin could be screened first with MTBDRplus.

KW - Molecular assays

KW - Resistance

KW - Rifampin

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84959226356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959226356&partnerID=8YFLogxK

U2 - 10.1016/j.ijmyco.2016.01.001

DO - 10.1016/j.ijmyco.2016.01.001

M3 - Article

AN - SCOPUS:84959226356

JO - International Journal of Mycobacteriology

JF - International Journal of Mycobacteriology

SN - 2212-5531

ER -